An open-label pilot study of St. John's wort in juvenile depression

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 42, Issue 8, 2003, Pages 908-914

  Findling, Robert L ^a   McNamara, Nora K ^a   O'Riordan, Mary Ann ^a   Reed, Michael D ^a   Demeter, Christine A ^a   Branicky, Lisa A ^a   Blumer, Jeffrey L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Depression; Hypericum perforatum; St. John's wort

Indexed keywords

HYPERICUM PERFORATUM EXTRACT;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERICUM PERFORATUM; MAJOR DEPRESSION; PHARMACODYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; TREATMENT RESPONSE; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG TOLERANCE; FEMALE; HOSPITALIZATION; HYPERICUM; MALE; OUTCOME ASSESSMENT; PHYTOTHERAPY; PILOT STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE;

ADOLESCENT; CHILD; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG TOLERANCE; FEMALE; HUMANS; HYPERICUM; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PHYTOTHERAPY; PILOT PROJECTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 0042330148     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CHI.0000046900.27264.2A     Document Type: Article

References (40)

1. American Academy of Child and Adolescent Psychiatry (1998), Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37:63-83
2. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
3. Barnes J, Anderson LA, Phillipson JD (2001), St. John's wort (Hypericum perforatum L): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 53:583-600
4. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J (1996), Child and adolescent depression: a review of the past 10 years. Part I J Am Acad Child Adolesc Psychiatry 35:1427-1439
5. Dunn LM, Dunn LM (1981), Peabody Picture Vocabulary Test-Revised Manual for Forms L and M. Circle Pine, MN: American Guidance Service
6. Emslie GJ, Heiligenstein JH, Wagner KD et al. (2002), Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215
7. Emslie GJ, Rush AJ, Weinberg WA et al. (1997), A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037
8. Ernst E (1995), St. John's wort, an antidepressant? A systematic, criteria-based review. Phytomedicine 2:67-71
9. Ernst E (1999), Prevalence of complementary/alternative medicine for children: a systematic review. Eur J Pediatr 158:7-11
10. Findling RL, Feeny NC, Stansbrey RJ, Delporto-Bedoya D, Demeter C (2002a), Somatic treatment for depressive illnesses in children and adolescents. Child Adolesc Psychiatr Clin North Am 11:555-578
11. Findling RL, Myers C, O'Riordan MA et al. (2002b), An open-label dosing study of paroxetine in depressed youths. Curr Ther Res 63:588-601
12. Horrigan JP, Sikich L, Courvoisie HE, Barnhill LJ (1998), Alternative therapies in die child psychiatric clinic. J Child Adolesc Psychopharmacol 8:249-250
13. Hübner WD, Kirste T (2001), Experience with St. John's Wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res 15:367-370
14. Hypericum Depression Trial Study Group (2002), Effect of Hypericum perforatum (St. John's Wort) in major depressive disorder: a randomized controlled trial. JAMA 287:1807-1814
15. Kalb R, Trautmann-Sponsel RD, Kieser M (2001), Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients: a randomized double-blind multicenter clinical trial. Pharmacopsychiatry 34:96-103
16. Kaufman J, Birmaher B, Brent D et al. (1997), Schedule for Affective Disorders and Schizophrenia for School-Age Children: Present and lifetime version (K-SADS-PL). Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988
17. Kazdin AE, Rodgers A, Colbus D (1986), The Hopelessness Scale for Children: psychometric characteristics and concurrent validity. J Consult Clin Psychol 54:241-245
18. Keller MB, Ryan ND, Strober M et al. (2001), Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772
19. Kessler RC, Avenevoli S, Ries Merikangas K (2001), Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 49:1002-1014
20. Kovacs M (1985), The Children's Depression Inventory (CDI). Psychopharmacol Bull 21:995-998
21. Kumar AM, Kumar M, Deepika K, Fernandez JB, Eisdorfer C (1990), A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelet and plasma. Life Sci 47:1751-1759
22. Kupfer DJ, Frank E (2002), Placebo in clinical trials for depression: complexity and necessity. JAMA 287:1853-1854
23. Lecrubier Y, Clerc G, Didi R, Kieser M (2002), Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 159:1361-1366
24. Leitenberg H, Yost LW, Carroll-Wilson M (1986), Negative cognitive errors in children: questionnaire development, normative data, and comparisons between children with and without self-reported symptoms of depression, low self-esteem, and evaluation anxiety. J Consult Clin Psychol 54:528-536
25. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996), St. John's wort for depression: an overview and meta-analysis of randomised clinical trials. Br Med J 313:253-258
26. Marsden CA, Tyrer P, Casey P, Seivewright N (1987), Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol 1:244-250
27. Murdoch D, McTavish D (1992), Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44:604-624
28. Nathan PJ (2001), Hypericum perforatum (St. John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 15:47-54
29. National Institute of Mental Health (1985a), Clinical Global Impressions Scale. Psychopharmacol Bull 21:839-843
30. National Institute of Mental Health (1985b), Dosage Record Treatment Emergent Symptom Scale (DOTES). Psychopharmacol Bull 21:1067-1068
31. National Institute of Mental Health (1985c), Treatment Emergent Symptoms Scale-Write-in (TESS). Psychopharmacol Bull 21:1069-1072
32. Philipp M, Kohnen R, Hiller KO (1999), Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 319:1534-1538
33. Poznanski EO, Freeman LN, Mokros HB (1985), Children's Depression Rating Scale-Revised. Psychopharmacol Bull 21:979-990
34. Robin A, Foster S (1989), Negotiating Parent-Adolescent Conflict. New York: Guilford
35. Rynn MA, Findling RL, Emslie GJ et al. (2002), Efficacy and Safety of Nefazodone in Adolescents with MDD. American Psychiatric Association Annual Meeting, Philadelphia, May 18-23
36. Shaffer D, Gould MS, Brasic J et al. (1983), A Children's Global Assessment Scale (CGAS) (for children 4 to 16 years of age). Psychopharmacol Bull 12:747-748
37. Shelton RC, Keller MB, Gelenberg A et al. (2001), Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285:1978-1986
38. Wagner KD, Robb AS, Findling R, Tiseo P (2002), Citalopram is effective in the treatment of major depressive disorder in children and adolescents: results of a placebo-controlled trial. Int J Neuropsychopharmacol 5:161
39. Wagner KD, Wohlberg C (2002), Efficacy and safety of sertraline for treatment of pediatric major depressive disorder. American Psychiatric Association Annual Meeting, Philadelphia, May 18-23
40. Walter G, Rey JM (1999), Use of St. John's wort by adolescents with a psychiatric disorder. J Child Adolesc Pychopharmacol 9:307-311